Keywords
Metabolic Syndrome
Obesity
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To verify the profile of patients diagnosed with Non-alcoholic Fatty Liver Disease by clinical, laboratory and anthropometric parameters. Methods: Cross-sectional, prospective, descriptive and analytical study, with patients over 18 years of age diagnosed with NAFLD by ultrasound, from October 2019 to February 2020. Results: 80 patients were selected to participate in the research, 24 excluded, resulting in 56 patients. observed the prevalence of women (64.28%), average age of the population of 55.28 years. On associated comorbidities, 78.6% had DM2 or Insulin Resistance, 75% SAH, and 66.9% some type of dyslipidemia. Anthropometric data, 83.93% showed a change in BMI; 91.07% in the value of abdominal circumference; 73.21% in the value of neck circumference, waist/ height ratio (RCE) outside the parameters of normality in 100% of patients. AST changed in 32.73% of the exams, ALT in 21.82% and GGT in 42%. Of the 56 patients, 50% had grade lI steatosis, 23.22% grade I, 12.50% grade Ill, and 14.29% classified as indeterminate. Conclusion: it is concluded that it is still necessary to strengthen the guidelines on non-pharmacological treatment for patients with NAFLD, in addition to encouraging healthy habits.
References
ALBERTI KG, et al.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome -- a new worldwide definition. Lancet. 2005;366(9491):1059-62.
ABESO. ASSOCIAÇÃO BRASILEIRA PARA O ESTUDO DA OBESIDADE E DA SÍNDROME METABÓLICA.2016. Diretrizes Brasileiras de Obesidade. Disponível em: https://abeso.org.br/diretrizes/. Acessado em: 5 de maio de 2023.
CHALASANI N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatol, 2018; 67(1): 328-357.
COELHO BC. Perfil clínico-epidemiológico dos pacientes com Doença Hepática Gordurosa Não Alcoólica acompanhados no serviço de gastroenterologia do Hospital Geral de Fortaleza. Trabalho de Conclusão de Curso (Residência Médica em Gastroenterologia) - Escola de Saúde Pública, Fortaleza, 2019;
COTTER TG e RINELLA M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenteroly, 2020; 158: 1851-1864
COTRIM HP. Doença hepática gordurosa não alcoólica: história natural. Gazeta Médica da Bahia, 2009; 79:46-47.
COTRIM HP, et al. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann Hepatol, 2011; 10:33.
DELLA JUNIOR AP, et al. Avaliação do risco cardiovascular segundo os critérios de Framinghan em adultos. RBCS [Internet]. 4º de agosto de 2016 [citado 6º de maio de 2023];20(3):183-8. Disponível em: https://periodicos.ufpb.br/index.php/rbcs/article/view/22697
FORTI AC, et al. Diretrizes da Sociedade Brasileira de Diabetes 2019-2020. Soc Bras. Diab. Arq. Bras. Cardiol. 2019; 53: 1689–99.
GARCIA GT, et al. Grau de Concordância entre Instrumentos de Estratificação de Risco Cardiovascular. Arq Bras Cardiol, 2017; 108: 427-435.
INTERNATIONAL DIABETES FEDERATION. The IDF consensus worldwide definition of the Metabolic Syndrome. 2006.
MALACHIAS MV, et al; Sociedade Brasileira de Cardiologia. 7ª Diretriz brasileira de hipertensão arterial. Arq Bras Cardiol. 2016;107(3 supl 3):1-83.
MALTA DC, et al. Doenças crônicas não transmissíveis e a utilização de serviços de saúde: análise da Pesquisa Nacional de Saúde no Brasil. RevSaúdePública, 2017; 51.
MARCHESINI G e MAZZOTTI A. NAFLD incidence and remission: Only a matter of weight gain and weight loss?. JournalOfHepatology, 2015; 62: 15-17.
MAURICE J e MANOUSOU P. Non-alcoholic fatty liver disease.ClinMed (Lond),2018; 18: 245-250.
MDCALC. 2020a. Fibrosis-4 (FIB-4) Index for Liver Fibrosis. Disponível em: https://www.mdcalc.com/calc/2200/fibrosis-4-fib-4-index-liver-fibrosis. Acessado em: 10 de janeiro de 2020.
MDCALC. 2020b. NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score. Disponível em: https://www.mdcalc.com/calc/3081/nafld-non-alcoholic-fatty-liver-disease-fibrosis-score. Acessado em: 10 de janeiro de 2020.
MIQUELITO J e CONCEIÇÃO SIQUEIRA E. Evolução da doença hepática gordurosa não alcoólica: revisão de literatura. R. Saúde, 2022;13(1):34-40.
MOIA LJMP, et al. Programa de Hepatopatias do Hospital da Fundação Santa Casa de Misericórdia do Pará - Infra-estrutura e epidemiologia clínica em 10 anos de atendimento. Rev Soc Bras Med Trop, 2004; 37.
PATERNOSTRO R e TRAUNER M. Current treatment of non-alcoholic fatty liver disease. JInternMed, 2022; 292: 190-204.
PELEG N, et al. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease. DigandLiverDis, 2017; 49(10): 1133-1138.
PORTELA CLM. Inter-relações entre síndrome metabólica, doença hepática gordurosa não alcoólica e fatores nutricionais em idosos hipertensos. Dissertação (Mestrado em Saúde Pública) - Universidade Estadual do Ceará, Ceará, 2010.
POUWELS S, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord, 2022; 22.
SALMANRONGHANI H, et al. Evaluation of neck circumference as an easy and reliable predictor for non-alcoholic fatty liver disease. Turk J Gastroenterol, 2019; 30: 163-70.
YOUNOSSI Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nature Reviews. Gastroenterolgy & Hepatology, 2018; 15.